EBS
Emergent
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
Signals Analysis
Buy signal 3
Sell signal 2
stock price surged significantly
consensus rating "Strong Buy"
Low Cash Short-term Debt Ratio
Revenue Beats Expectation
EPS Below Expectations
Key Stats
--DAY`S RANGE--
--52 WK RANGE--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
About EBS
Emergent Biosolutions Inc.
A company that develops vaccines and therapeutics against biological agents which are potential weapons
Biological Technology
Invalid Date
11/15/2006
New York Stock Exchange
900
12-31
Common stock
300 Professional Drive
, Gaithersburg
, MD 20879
--
Emergent Biosolutions Inc., founded in May 1998 in Michigan, USA, was changed to Delaware Corporation in June 2004. The company has two operating divisions: Biodefense and Bioscience. The company is a global life sciences company focused on providing innovative preparedness and response solutions to unexpected, intentional and naturally occurring public health threats.
Company Financials
EPS
EBS has released its 2024 Q4 earnings. EPS was reported at 0.05, versus the expected -0.50, beating expectations. The chart below visualizes how EBS has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
EBS has released its 2024 Q4 earnings report, with revenue of 194.70M, reflecting a YoY change of -29.61%, and net profit of -31.30M, showing a YoY change of 36.77%. The Sankey diagram below clearly presents EBS’s revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
